The impact of tumour volume and other characteristics on uptake of radiolabelled monoclonal antibodies in tumour tissue of head and neck cancer patients

European Journal of Nuclear Medicine

Volumn 25, Issue 11, 1998, Pages 1562-1565

  De Bree, Remco ^a   Kuik, Dirk J ^a   Quak, Jasper J ^a   Roos, Jan C ^a   Van Den Brekel, Michiel W M ^a   Castelijns, Jonas A ^a   Van Wagtendonk, Frank W ^a   Greuter, Henri ^a   Snow, Gordon B ^a   Van Dongen, Guus A M S ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Head and neck cancer; Monoclonal antibodies; Radioimmunotherapy; Tumour uptake; Tumour volume

Indexed keywords

MONOCLONAL ANTIBODY; TUMOR ANTIGEN;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HEAD AND NECK CANCER; HUMAN; ISOTOPE LABELING; MALE; MINIMAL RESIDUAL DISEASE; MULTIVARIATE ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PROGNOSIS; RADIOACTIVITY; RADIOIMMUNOTHERAPY; RANDOMIZED CONTROLLED TRIAL; SQUAMOUS CELL CARCINOMA; TUMOR BIOPSY; TUMOR DIFFERENTIATION; TUMOR VOLUME;

AGED; ANTIBODIES, MONOCLONAL; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; REGRESSION ANALYSIS; TECHNETIUM COMPOUNDS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 15144355536     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002590050336     Document Type: Article

References (10)

1. Alvi A, Johnson JT. Development of distant metastases after treatment of advanced-stage head and neck cancer. Head Neck 1997; 19:500-505.
2. Wessels BW, Harisiadis L, Carabell SC. Dosimetry and radiobiological efficacy of clinical radioimmunotherapy. J Nucl Med 1989; 30:827.
3. 2 in patients with head and neck cancer. Clin Cancer Res 1995; 1:277-286.
4. 99mTc-labeled monoclonal antibody U36 in patients with head and neck cancer. Clin Cancer Res 1995; 1:591-598.
5. Castelijns JA, Van den Brekel MWM, Smit EMT, Tobi H, Van Wagtendonk FW, Golding RP, Venema HW, Van Schaik C, Snow GB. Predictive value of MRI imaging-dependent and non-MRI-dependent parameters for recurrence of laryngeal cancer after radiation therapy. Radiology 1995; 196:735-739.
6. Jain RK. Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res 1990; 50:814s-819s.
7. Chatal J-F, Saccavini J-C, Gestin J-F, Thédrez P, Curtet C, Kremer M, Guerreau D, Nobilé D, Fumoleau P, Guillard Y. Biodistribution of indium-111-labeled OC 125 monoclonal antibody intraperitoneally injected into patients operated on for ovarian carcinomas. Cancer Res 1989; 49:3087-3094.
8. Williams LE, Bares RB, Fass J, Hauptmann S, Schlumpelick V, Buell U. Uptake of radiolabeled anti-CEA antibodies in human colorectal primary tumors as a function of tumor mass. Eur J Nucl Med 1993 29:345-347.
9. Van Hof AC, Molthoff CFM, Davies Q, Perkins AC, Verheijen RHM, Kenemans P, Den Hollander W, Wilhelm AJ, Baker TS, Sopwith M, Frier M, Symonds EM, Roos JC. Biodistribution of indium-111-labeled engineered human antibody CTMO1 in ovarian cancer patients: influence of protein dose. Cancer Res 1996; 56:5179-5185.
10. 186Re-labeled monoclonal antibody E48. Cell Biophys 1994; 24:135-142.